STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: Pimozide was identified as an indirect inhibitor of STAT5 signaling and demonstrated to decrease the survival of chronic myelogenous leukemia cells that were resistant to the kinase inhibitors [39].